Cullinan Therapeutics, Inc. (CGEM)
(Real Time Quote from BATS)
$22.51 USD
-0.99 (-4.21%)
Updated Jun 3, 2024 01:02 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CGEM 22.51 -0.99(-4.21%)
Will CGEM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CGEM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEM
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
CGEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
Other News for CGEM
Cullinan Management’s Zipalertinib Shows Lung Cancer Trial Promise
TD Cowen Sticks to Its Buy Rating for Cullinan Management (CGEM)
Stifel Nicolaus Reaffirms Their Buy Rating on Cullinan Management (CGEM)
Analysts’ Top Healthcare Picks: Autolus Therapeutics (AUTL), Affimed (AFMD)
Buy Recommendation Backed by Promising Clinical Results for Cullinan Management’s Oncology Drugs